North America is expected to hold the dominant position in the global somatropin market due to growing FDA approval for a new product launch

 

The growing prevalence of growth hormone deficiency is driving the growth of the global somatropin market growth. According to an article published in the Springer Nature journal in February 2017, the prevalence of growth hormone deficiency in children is within the range of 1.8 to 2.9 per 10,000 in Europe and the U.S. Increasing approval of various somatropin products by regulatory authorities such as the U.S. Food and Drug Administration (FDA) is again fostering the growth of the market. For instance, in July 2018, Ferring Pharmaceuticals Inc. received approval from the U.S. Food and Drug Administration for ZOMACTON, a somatropin injection, for the following additional pediatric indications. Short stature due to Turner syndrome, Idiopathic short stature (ISS), and Short stature born small for gestational age (SGA) with no catch-up growth by 2 to 4 years.

North America is expected to hold the dominant position in the global somatropin market due to growing FDA approval for a new product launch. For instance, in September 2020, The U.S. Food and Drug Administration approved Sogroya (somapacitan) for adults with growth hormone deficiency. Sogroya is the first human growth hormone (hGH) therapy that adult patients only take once a week by injection under the skin; other FDA-approved hGH formulations for adults with growth hormone deficiency must be administered daily.

In October 2020, Pfizer Inc. and OPKO Health Inc. announced that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in children 3 to <18 years of age with growth hormone deficiency (GHD), met its primary endpoint of improved treatment burden compared to GENOTROPIN® (somatropin) for injection administered once-daily.

Key players engaged in the global somatropin market are Novo Nordisk A/S, Pfizer, Inc., GeneScience Pharmaceuticals, Eli Lilly and Company, Sandoz International, LG Life Sciences, Ipsen Inc., Merck KGaA, F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., and Ferring Pharmaceuticals.

Somatropin, also called human growth hormone in its natural form, is basically a peptide hormone that promotes cell growth, cell generation, and cell regeneration in our body. In fact, it has been clinically proven that it can stimulate the production of growth hormones and supply energy to our cells. So it's very important in human growth. There are many benefits of somatropin and it is used to treat various health conditions such as increased muscle mass, decreased fat, increased stamina decreased cholesterol, and increase insulin sensitivity.